Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Bioelectronics's Revenue for the
three
months ended in . 20 was $0.00 Mil. Bioelectronics's average Accounts Receivable for the
three
months ended in . 20 was $0.00 Mil.
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Bioelectronics Receivables Turnover Related Terms
Bioelectronics Receivables Turnover Historical Data
* Premium members only.
The historical data trend for Bioelectronics's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bioelectronics Receivables Turnover Chart
Bioelectronics Annual Data
Trend
Receivables Turnover
Bioelectronics Quarterly Data
Receivables Turnover
BIEL vs NUVPF, ADMD, RSPI: Receivables Turnover Comparison
For the Medical Devices subindustry, Bioelectronics's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bioelectronics Receivables Turnover vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Bioelectronics's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Bioelectronics's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bioelectronics (BIEL) has a Receivables Turnover of 0.00 as of . 20. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Bioelectronics and its competitors.
Is Bioelectronics' Receivables Turnover too high?
Bioelectronics' current Receivables Turnover is 0.00.
How does Bioelectronics' Receivables Turnover compare to NUVPF and ADMD?
Bioelectronics' Receivables Turnover of 0.00 can be compared against companies in the Medical Devices & Instruments industry. The industry median Receivables Turnover is 5.51. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Medical Devices & Instruments company?
The median Receivables Turnover among Medical Devices & Instruments companies is 5.51, based on 812 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Bioelectronics and its competitors. For the Medical Devices & Instruments industry, the median Receivables Turnover is 5.51 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bioelectronics's current Receivables Turnover is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bioelectronics stock overvalued right now?
Bioelectronics (BIEL) has a current Receivables Turnover of 0.00. The current Receivables Turnover is 0.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Bioelectronics (BIEL), the current Receivables Turnover is 0.00 as of . 20. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Bioelectronics Corp is an electroceutical company. The company develops wearable, neuromodulation devices to safely mitigate neurological diseases and improve quality of life. Its product line includes Actipatch Musculoskeletal Pain Therapy, Allay menstrual pain therapy, Smart insole heel pain therapy, and Recovery RX post operative and Chronic wounds therapy. It sells its products to wholesale distributors, directly to hospitals and clinics, and to consumers. develops & commercializes electrical stimulation/neuromodulation technology. Company products include RecoveryRx, ActiPatch Musculoskeletal Pain Relief, and Others.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BIEL has been successfully added to your 
